Tillkännagivande • Mar 26
PsyBio Therapeutics Listing Transfer from Tier 2 to NEX In accordance with TSX Venture Policy 2.5, PsyBio Therapeutics Corp. has not maintained the requirements for a TSX Venture Tier 2 company. Therefore, effective at the opening on March 27, 2024, the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Toronto to NEX. As of March 27, 2024, the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. The trading symbol for the Company will change from PSYB to PSYB.H. There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital. The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market. Further to the TSX Venture bulletin dated December 6, 2023, trading in the shares of the Company will remain suspended. Members are prohibited from trading in the securities of the Company during the period of the suspension or until further notice. Tillkännagivande • Jan 11
PsyBio Therapeutics Corp. Appoints Ian Wisenberg to the Board of Directors PsyBio Therapeutics Corp. announced the addition of life sciences veteran Ian Wisenberg to the Company's board of directors (the "Board") and as an independent member of the Company's audit committee. Mr. Wisenberg's career spans over three decades in biotechnology international business with an emphasis in finance, capital formation, corporate and business development. Ian has been an integral leader charting innovation and growth across several Bridgewest Group biotech companies. As CEO and board director of BioCina Pty Ltd., he leads a highly accomplished team, recognized for its strong history as a multi-product biologics development and manufacturing. Prior to taking the helm at BioCina, Ian was founder and Chief Business Officer of BioArdis, Chief Financial Officer at BioDuro and previous to these roles ran a very successful global life sciences consulting practice, BioGlobal Consulting Group, which had an extensive client list of biotech and pharma companies in the USA and abroad. Ian is from Cape Town, South Africa, and attended the University of Cape Town. Tillkännagivande • Dec 10
PsyBio Therapeutics Corp. Files Three New Provisional Patent Applications, Including Intellectual Property Protection for Biosynthetic Production of 5-MeO-DMT PsyBio Therapeutics Corp. announced the filing of three additional U.S. Provisional Patent Applications covering its new discoveries. This bring the total number of provisional applications filed by PsyBio to nineteen. The National Park Service posted a request recently warning visitors not to lick the Sonoran Desert Toad (Incilius alvarius), as reported online by the Smithsonian Magazine. The report describes that widespread use of 5-MeO-DMT could have disastrous effects for Sonoran Desert Toads and, as a result, that conservationists are urging people to use synthetic alternatives. The three provisional patent applications comprise advancements concerning production methodology, host strains and processes of production that further support and allow PsyBio's novel production platform methodology to be patent protected including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT, which is environmentally safer than synthetic production methodology. Tillkännagivande • Dec 07
PsyBio Therapeutics Corp. Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio PsyBio Therapeutics Corp. announced the filing of four new U.S. Patent Cooperation Treaty (PCT) Patent Applications seeking to convert five provisional patent applications. This brings the total number of PCT conversion filings completed by PsyBio to ten. The four U.S. PCT Patent Applications were filed based upon five provisional patents comprising advancements concerning production methodology, host strains and processes of production that are expected to support and allow PsyBio's novel production methodology to be patent protected. These filings demonstrate the company's ongoing commitment to value creation while promoting scientific and methodologic advancements in the field. Tillkännagivande • Dec 02
PsyBio Therapeutics Corp. announced that it expects to receive CAD 1 million in funding PsyBio Therapeutics Corp. announced a non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on December 1, 2022. Each unit will consist of one subordinate voting share and one share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at an exercise price of CAD 0.10 per warrant share for a period of two years from the first closing date, or 30 days after the date on which the company gives notice of acceleration, which notice may be provided no earlier than four months and twenty-one days from the date of issue if the closing price of the common shares on a stock exchange in Canada is higher than CAD 0.20 per common share for more than 10 non-consecutive trading days. Closing of the offering may be completed in multiple tranches and is subject to certain closing conditions including, but not limited to, conditional approval from the TSX Venture Exchange and receipt of any other required regulatory approvals. The securities being offered under the offering will be issued pursuant to applicable exemptions from the prospectus requirements under applicable securities laws and will be subject to a hold period that will expire four months and one day from the date of issue. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Bob Oliver was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Aug 09
PsyBio Therapeutics Corp. Announces Expansion of Patent Portfolio with Additional Global Patent Applications PsyBio Therapeutics Corp. announced the filing of additional international patent applications in Europe, Africa, and Asia. This brings PsyBio's total number of patent application submissions to twenty, making it one of the most robust portfolios in the sector. The patent applications submitted comprise advancements concerning production methodology, host strains and processes of production that support and allow PsyBio's novel production methodology to be globally protected. These filings demonstrate the Company's commitment to value creation, while also promoting scientific and methodologic advancements in the field. Tillkännagivande • Jun 04
PsyBio Therapeutics Corp. Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds PsyBio Therapeutics Corp. has initiated formal process development for commercially scalable, patent pending manufacturing technology expected to enable Good Manufacturing Practice ("GMP") production. PsyBio's manufacturing process utilizes bioreactor manufacturing technology to facilitate expansion of PsyBio's portfolio of compounds. This process methodology is another necessary component for the Chemistry, Manufacturing and Controls section ("CMC") for its therapeutic candidate portfolio Investigational New Drug ("IND") applications with the United States Food and Drug Administration ("FDA"). PsyBio retains the global, exclusive, and perpetual right to license a platform technology enabling rapid generation of tryptamines and related compounds through a biosynthetic process using genetically modified bacteria and has demonstrated the ability to manufacture one of its first promising therapeutic candidates at commercial scale. Commercial purification process development furthers the ability to manufacture compounds with predictable and reproducible purity. Tillkännagivande • May 31
Psybio Therapeutics Corp. Provides Corporate Update on Intellectual Property and Clinical Development Milestones PsyBio Therapeutics Corp. provided shareholders with a corporate update. Intellectual Property and Clinical Development Milestones e Company recently announced that it achieved a commercially scalable purification method for one of its second-generation compounds. This purification process methodology is a necessary component for the Chemistry, Manufacturing and Controls section for an Investigational New Drug application with the United States Food and Drug Administration. The Company recently announced that it expanded its preclinical pipeline activities by initiating blood-brain barrier permeability testing. Favorable results from this type of testing are anticipated to expediate compound selection and progress toward the filing of an IND application with the FDA. The Company recently announced that it submitted an application to convert existing provisional patents to full patents. This submission covers major markets including North America, Europe, Asia-Pacific, and Africa as well as other important countries. The continued collaboration with Miami University is anticipated to expedite progress toward the filing of an IND application with the FDA. The Company recently announced that it is initiating the process of recruiting, evaluating, and selecting highly qualified investigators for upcoming clinical trials. The Company recently announced that it is in the process of drafting its second pre-IND application in anticipation of seeking IND approval from the FDA for clinical trials. Tillkännagivande • May 18
PsyBio Therapeutics Corp. Develops Commercial Purification Process for Second Generation Psycho-Targeted Compound PsyBio Therapeutics Corp. reported that it has achieved a commercially scalable purification method for one of its second generation compounds. This manufacturing process achievement is expected to enable the commercial scale purification of bioreactor produced products utilizing manufacturing methodology to further expand PsyBio's portfolio of compounds that can be more readily and rapidly developed than competitive methods. This purification process methodology is a necessary component for the Chemistry, Manufacturing and Controls section ("CMC") for this second-generation candidates Investigational New Drug application with the US Food and Drug Administration. PsyBio retains the global, exclusive, and perpetual right to license a platform technology enabling rapidgeneration of tryptamines and related compounds through a biosynthetic process using genetically modifiedbacteria and has demonstrated the ability to manufacture one of its first promising therapeutic candidates atcommercial scale. Commercial purification process development furthers the ability to manufacture compoundswith predictable and reproducible purity. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Bob Oliver was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 14
PsyBio Therapeutics Corp. Initiates Clinical Trial Site Selection Process PsyBio Therapeutics Corp. announced that it is initiating the process of recruiting, evaluating and selecting highly qualified investigators for upcoming clinical trials. PsyBio is currently in the process of drafting its second pre-IND application in anticipation of seeking investigational new drug ("IND") approval from the United States Food and Drug Administration for upcoming clinical trials. Once submitted and approved by the appropriate regulatory authorities, including the FDA, clinical investigators will be selected and trained to conduct clinical investigations, which will help facilitate rapid trial initiation and completion. Tillkännagivande • Apr 13
PsyBio Therapeutics Corp., Annual General Meeting, Jun 16, 2022 PsyBio Therapeutics Corp., Annual General Meeting, Jun 16, 2022. Tillkännagivande • Sep 24
PsyBio Therapeutics Announces Pre-IND Application Request Has Been Submitted to the United States Food and Drug Administration PsyBio Therapeutics Corp. reported it has submitted its first pre-Investigational New Drug ("IND") application meeting request to the United States Food and Drug Administration ("FDA") as part of the regulatory submission process. The FDA'sPre-Investigational New Drug Application (IND) Consultation Program fosters early communications between sponsors and new drug review divisions to provide guidance on the data necessary to warrant IND submission.[1] PsyBio is dedicated to working towards obtaining all necessary regulatory approvals for its therapeutics under development and intends to submit its most promising potential therapeutic candidates to the appropriate regulatory body as part of the approval process. The submission of this pre-IND meeting request for collaborative discussions with the FDA has been submitted in anticipation of filing the first of several clinical IND packages. Tillkännagivande • Jul 15
PsyBio Therapeutics Corp. Files A New Provisional Patent Application with the United States Patent and Trademark Office Entitled Psilocybin and Norbaeocystin Compositions and Methods of Treatment PsyBio Therapeutics Corp. filed a new provisional patent application with the United States Patent and Trademark Office entitled Psilocybin and Norbaeocystin Compositions and Methods of Treatment. The Patent Application contains 67 new inventive claims and further demonstrates the Company's vision to build a strong intellectual property portfolio protecting numerous novel psychedelic drug candidatesbeing developed for clinical trial evaluations. PsyBio's intellectual property portfolio now includes five pending provisionals and one pending non-provisional patent application. Tillkännagivande • Jun 23
Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds PsyBio Therapeutics Corp. has initiated its first, European pilot scale batch manufacturing of its psychedelic portfolio of compounds
with the proprietary biosynthetic formulation of psilocybin in collaboration with Biose Industrie ("Biose"), an expert in commercializing pharmaceutical products based on live bacterial production, to prepare products and substances for ongoing regulatory evaluation. Executive Departure • Apr 30
Director has left the company On the 21st of April, Gerald Goldberg's tenure as Director ended after less than a year in the role. We don't have any record of a personal shareholding under Gerald's name. Gerald is the only executive to leave the company over the last 12 months. Tillkännagivande • Mar 03
PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Albany Molecular Research Inc PsyBio Therapeutics Corp. has initiated pilot scale-up of its proprietary biosynthetic formulation of psilocybin in collaboration with Albany Molecular Research Inc. The Company has completed Phase I of this process, including technology transfer activities, preparation of strain banks, and the adoption of analytical methods and looks forward to communicating additional progress.